Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

37.55
-0.3000-0.79%
Volume:354.69K
Turnover:13.37M
Market Cap:1.41B
PE:-37.58
High:38.00
Open:37.92
Low:37.40
Close:37.85
52wk High:54.85
52wk Low:28.54
Shares:37.49M
Float Shares:28.93M
Volume Ratio:0.87
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9993
EPS(LYR):-0.1400
ROE:-116.07%
ROA:-0.45%
PB:92.61
PE(LYR):-268.21

Loading ...

Harrow Q2 Revenue Slightly Beats Estimates

Reuters
·
Aug 11

Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate

Benzinga Earnings
·
Aug 11

Harrow Inc Q2 EPS USD -0.46

THOMSON REUTERS
·
Aug 11

Harrow Inc Q2 Gross Margin 71%

THOMSON REUTERS
·
Aug 11

B. Riley Securities Keeps Their Buy Rating on Harrow Health (HROW)

TIPRANKS
·
Aug 10

Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
Aug 07

Arista Networks Stock Leads Fast Growth Picks With High Insider Ownership

Simply Wall St.
·
Aug 07

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Benzinga Earnings
·
Aug 07

Viatris Raises Annual Profit Forecast on Branded Drug Strength

Reuters
·
Aug 06

Harrow to Buy Dry Eye Nasal Spray Tyrvaya from Viatris for up to $100 Million

Reuters
·
Aug 06

Harrow Inc: Expects to Fund Upfront Cash Payment Using Cash on Hand

THOMSON REUTERS
·
Aug 06

Harrow, - Deal Expected to Close in Second Half of 2026

THOMSON REUTERS
·
Aug 06

Harrow Acquires Global Rights to Tyrvaya®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

THOMSON REUTERS
·
Aug 06

Harrow, - Deal Valued at up to $100 Mln with $30 Mln Cash at Closing

THOMSON REUTERS
·
Aug 06

Earning Preview: Harrow Health Inc revenue is expected to increase by 6.59%, and institutional views are bullish

Earnings Agent
·
Aug 03

Harrow Updates Financial Calendar with Upcoming Quarterly Results Release and Investor Call

Reuters
·
Jul 27

Harrow Price Target Maintained with a $63.00/share by BTIG

Dow Jones
·
Jul 21

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

GlobeNewswire
·
Jul 20

Harrow Says QUELL Trial of Iheezo Posts Topline Data in Q4 2026

Reuters
·
Jul 20

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

GlobeNewswire
·
Jul 20